COST-EFFECTIVENESS OF EMICIZUMAB VERSUS BY-PASSING AGENTS IN PATIENTS WITH HAEMOPHILIA A AND FVIII INHIBITORS IN FRANCE: PF331

2019 
    • Correction
    • Source
    • Cite
    • Save
    • Machine Reading By IdeaReader
    0
    References
    0
    Citations
    NaN
    KQI
    []